Robson ME, Im SA, Senkus E, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). J Clin Oncol 35, 2017 (suppl; abstr LBA4).
Mutaties in ESR1 in circulerend tumor-DNA van patiënten met mammacarcinoom: klinische betekenis
dec 2017 | Borstkanker